Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
18 December 2017

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Dr Reddys Laboratories Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 2,371.50
Net Changes 60.85
Volume 743680
Prev Close 2,310.65
2,371.50 60.85 (2.63%)
Date: Dec 15,2017 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 2325.95 Div Yield (%) 1.01
Buy (Size) 0.00(×0) Eps(Rs) 45.52
Sell (Size) 0.00(×0) Book Value(Rs) 682.0079709
Buy Quantity 0 Market Cap(Rs.Cr) 39348.46
Sell Quantity 0 Face Value(Rs) 5
Today's High 2380 Market Lot 1
Today's Low 2315 AGM Date Jul
52-Week High 3203.95 Book Closure Date Jul
52-Week Low 1901.65 ISIN No. INE089A01023

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 0 0.00
Indian (Promoter & Group) 44398828 26.77
Total of Promoter 44398828 26.77
Non Promoter (Institution) 71571697 43.15
Non Promoter (Non-Institution) 49908752 30.09
Total Non Promoter 121480449 73.23
Total Promoter & Non Promoter 165879277 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 165879277 100.00

Company News

12-Dec-2017  Dr Reddy's spurts after getting EIR for Bachupally facility
Dr Reddy's spurts after getting EIR for Bachupally facility

The announcement was made after market hours yesterday, 11 December 2017.

Meanwhile, the S&P BSE Sensex was down 102.53 points or 0.31% at 33,353.26.

On the BSE, 34,000 shares were traded on the counter so far as against the average daily volumes of 61,827 shares in the past one quarter. The stock had hit a high of Rs 2,328 and a low of Rs 2,274 so far during the day. The stock had hit a 52-week high of Rs 3,215 on 9 December 2016. The stock had hit a 52-week low of Rs 1,901.65 on 11 August 2017.

The large-cap company has equity capital of Rs 82.94 crore. Face value per share is Rs 5.

Dr. Reddy's Laboratories said that the company has received an Establishment Inspection Report (EIR) from the USFDA yesterday, 11 December 2017 as closure of audit for the Bachupally, Hyderabad facility.

Earlier, the company had on 28 April 2017 informed about the audit of its Formulations Manufacturing Plant - 3 at Bachupally, Hyderabad by the USFDA, wherein it was issued a form 483 with 11 observations.

On a consolidated basis, Dr Reddy's Laboratories' net profit fell 1.1% to Rs 305.40 crore on 1.88% decline in total income to Rs 3591.40 crore in Q2 September 2017 over Q2 September 2016.

Dr Reddy's Laboratories is an integrated global pharmaceutical company.

12-Dec-2017  Dr Reddys Laboratories receives EIR for its facility at Bachup...
Dr Reddys Laboratories receives EIR for its facility at Bachupally, Hyderabad

Dr Reddys Laboratories has received an Establishment Inspection Report from the USFDA on 11 December 2017 following closure of audit of its Formulations Manufacturing Plant 3 at Bachupally, Hyderabad by the USFDA, where in the Company received a Form 483 with 11 observations.
12-Dec-2017  Other announcement of Dr. Reddy's Laboratories Ltd
Other announcement of Dr. Reddy's Laboratories Ltd

Intimation
12-Dec-2017  Dr. Reddy's Laboratories Limited - Updates
Dr. Reddy's Laboratories Limited - Updates

Dr. Reddy's Laboratories Limited has informed the Exchange regarding 'Intimation'.
04-Dec-2017  Dr Reddy's gets healthier after USFDA clears facility
Dr Reddy's gets healthier after USFDA clears facility

The announcement was made after market hours on Friday, 1 December 2017.

Meanwhile, the S&P BSE Sensex was up 108.35 points or 0.34% at 32,944.77.

On the BSE, 12,024 shares were traded on the counter so far as against the average daily volumes of 65,421 shares in the past one quarter. The stock had hit a high of Rs 2,278.50 and a low of Rs 2,240 so far during the day. The stock had hit a 52-week high of Rs 3,247 on 1 December 2016. The stock had hit a 52-week low of Rs 1,901.65 on 11 August 2017.

The stock had underperformed the market over the past one month till 1 December 2017, falling 5.53% compared with the Sensex's 2.28% decline. The stock had also underperformed the market over the past one quarter, advancing 0.59% as against the Sensex's 2.95% rise. The scrip had also underperformed the market over the past one year, dropping 31.17% as against the Sensex's 23.62% rise.

The large-cap company has equity capital of Rs 82.94 crore. Face value per share is Rs 5.

On 21 September 2017, Dr Reddy's Laboratories had announced that the audit of its Custom Pharmaceutical Services (CPS) facility, Technology Development Centre (TDC-1) at Miyapur, Hyderabad, Telangana, by the United States Food & Drug Administration (USFDA) was completed on that day with zero observations.

On a consolidated basis, Dr Reddy's Laboratories' net profit fell 1.1% to Rs 305.40 crore on 1.1% decline in net sales to Rs 3546 crore in Q2 September 2017 over Q2 September 2016.

Dr Reddy's Laboratories is an integrated global pharmaceutical company.

01-Dec-2017  Dr Reddys Laboratories receives EIR for its Custom Pharmaceuti...
Dr Reddys Laboratories receives EIR for its Custom Pharmaceutical Services facility in Miyapur, Telangana

Dr Reddys Laboratories has received Establishment Inspection Report (EIR) from USFDA for its Custom Pharmaceutical Services facility, Technology Department Centre at Miyapur, Hyderabad, Telangana.
01-Dec-2017  Other announcement of Dr. Reddy's Laboratories Ltd
Other announcement of Dr. Reddy's Laboratories Ltd

Intimation regarding receipt of EIR.
01-Dec-2017  Dr. Reddy's Laboratories Limited - Press Release
Dr. Reddy's Laboratories Limited - Press Release

Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated December 01, 2017, titled 'Dr. Reddy?s Announces Approval of Impoyz? (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval'.
01-Dec-2017  Dr. Reddy's Laboratories Limited - Updates
Dr. Reddy's Laboratories Limited - Updates

Dr. Reddy's Laboratories Limited has informed the Exchange regarding 'Intimation regarding receipt of EIR.'.
30-Nov-2017  Dr Reddys Laboratories' CAPA plan accepted by Regulatory Autho...
Dr Reddys Laboratories' CAPA plan accepted by Regulatory Authority of Germany

Dr Reddys Laboratories announced that with regard to the audit conclusion of the Company's formulations manufacturing facility in Duvvada, Vishakhapatnam, by the Regulatory Authority of Germany, the CAPA plan submitted by the Company has been accepted by the Regulator. Consequently, the Regulator has permitted production to start again from this facility for the EU market. The Regulator will re-inspect this facility by end 2018.
Incorporation Year 1984 
Registered Office 8-2-337 Road No 3,Banjara Hills,
Hyderabad,
Telangana-500034
Telephone 91-40-49002900 
Fax 91-40-49002999 
Chairman Satish Reddy
Managing Director NA
Company Secretary Sandeep Poddar 
Auditor S R Batliboi & Associates LLP 
Face Value(Rs)
Market Lot
Listing MSEI,BSE,New York,NSE 
Registrar Big Share Services Pvt Ltd
3rd Flr 306 Rightwin,Amrutha Ville,Somajiguda,Hyderabad-500082 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS